Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 16, 2011, Pages

  Tonelli, Marcello ^a,c,d   Lloyd, Anita ^a,c,d   Clement, Fiona ^b   Conly, Jon ^c,d   Husereau, Don ^e   Hemmelgarn, Brenda ^b,c,d   Klarenbach, Scott ^c,d,e   McAlister, Finlay A ^a   Wiebe, Natasha ^c,d,e   Manns, Braden ^b,c,d,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Alberta Kidney Disease Network   (Canada)

^d Alberta Kidney Disease Network   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG POTENCY; DRUG SAFETY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION;

EID: 81055137319     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101280     Document Type: Article

References (60)

1. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
2. National Cholesterol Education Program (NCEP) Expert Panel. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda (MD): National Institutes of Health; 2002.
3. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treat ment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
4. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and wo men with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
5. Canadian Agency for Drugs and Technologies in Health. Requirements for health technology assessment template for reports. Ottawa (ON): The Agency; 2008.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
7. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160.
8. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243-54.
9. Pearson ES. The application of statistical methods to industrial standardization and quality control. London (UK): British Standards Institution; 1960.
10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-32.
11. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53. (Pubitemid 351640675)
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
13. Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Vol 2. London (UK): BMJ Books; 2001. p. 87-108.
14. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. JAMA 1995;273:408-12.
15. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
16. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9. (Pubitemid 26070113)
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
18. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73. (Pubitemid 34746063)
19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315: 629-34. (Pubitemid 27387172)
21. Schunemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford (UK): The Cochrane Collaboration; 2011.
22. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. (Pubitemid 27341818)
23. Bone HG, Kiel DP, Lindsay RS, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a doubleblind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007;92:4671-7. (Pubitemid 350223443)
24. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368:1155-63. (Pubitemid 44444932)
25. Di Lullo L, Addesse R, Comegna C, et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Ther 2005;22:601-12.
26. Holmberg B, Brannstrom M, Bucht B, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol 2005;39:503-10. (Pubitemid 41722034)
27. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005;45:473-84. (Pubitemid 40341326)
28. Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives [Hypertension High Risk Management trial (HYRIM)]. Atherosclerosis 2005;178:387-97. (Pubitemid 40193456)
29. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-9. (Pubitemid 39602790)
30. Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004;35:2807-12. (Pubitemid 39565175)
31. Asselbergs FW, Diercks GFH, Hillege HL, et al.; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and prava - statin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16. (Pubitemid 39473602)
32. Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004;19:737-44. (Pubitemid 41094384)
33. Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol 2003;12:225-31. (Pubitemid 37243068)
34. Crouse JR III, Raichlen JS, Riley WA, et al. Effect of rosuva - statin on progression of carotid intima-media thickness in lowrisk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007;297:1344-53. (Pubitemid 46513235)
35. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150:1064.
36. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. (Pubitemid 36398384)
37. Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study [KLIS]. J Atheroscler Thromb 2000;7:110-21.
38. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lova - statin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87.
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT- LLT). JAMA 2002;288:2998-3007.
41. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
42. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study [CAIUS]. Am J Med 1996;101:627-34. (Pubitemid 27150041)
43. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7.
44. Bak AA, Huizer J, Leijten PA, et al. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middleaged men free from cardiovascular disease. J Intern Med 1998;244:371-8. (Pubitemid 28513124)
45. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
46. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956-64.
47. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation 2010;121:306-14.
48. Fassett RG, Robertson IK, Ball MJ, et al. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised doubleblind placebo-controlled trial [LORD study]. Atherosclerosis 2010;213:218-24.
49. Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 2010;5:1928-38.
50. Yun KH, Shin IS, Park EM, et al. Effect of additional statin therapy on endothelial function and prognosis in patients with vasospastic angina. Korean Circ J 2008;38:638-43.
51. Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. 5.1.0 ed. Oxford (UK): The Cochrane Collaboration; 2011.
52. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
53. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)
54. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. (Pubitemid 32097262)
55. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
56. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31.
57. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-96. (Pubitemid 39140624)
58. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85. (Pubitemid 44127567)
59. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. (Pubitemid 35379733)
60. McAlister FA. The "number needed to treat" turns 20 - and continues to be used and misused. CMAJ 2008;179:549-53.